☰
icon-rus icon-eng

Поиск

Материалы ASCO-SITC Clinical Immuno-Oncology Symposium 2018
ASCO_STIC
 4 июн. 2018 г.
 admin@melanomapro.ru

Katy K. Tsai. Integration of Immune Chekpoint Inhibitors in Melanoma

Malcolm Brenner. Increasing the Efficacy and Safety of CAR T-Cell Therapy

N.Rizvi. Lung cancer IO landscape.

R.Dreicer. How will tuday presentations impact clinical practice?

Aaron M.Goodman. PD-L1(CD-274) Amplification: Incidence in 117344 tumors and checpoint blockade response.

Shivaani Kummar. Trial-design of early-phase testing of new agents

Aaron M.Goodman. PD-L1(CD-274) Amplification: Incidence in 117344 tumors and checpoint blockade response. Part 2.

Jeffrey Lemons. Safety and clinical activity of pembrolizumab immunotherapy and multiorgan site ablative stereotactic body radiotherapy (iMOSART) in patients with advanced solid tumors.

Colin Dinney. Checkpoint blockade for NMIBC.

Sergio Rutella. Capturing the complexity of the immune microenvironment of acute myeloid leukemia with 3D biology technology.

Jeremy Abramson. High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration.

Kristen Fousek. Targeting CD19-negative relapsed B-acute lymphoblastic leukemia using trivalent CAR T cells.

David Hong. Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression.

David Leung. Whole body PD-L1 PET in patients with NSCLC and melanoma.

Deborah J.L Wong. Novel combinations and imaging techniques for immunotherapy.

Jeffrey Bluestone . The Future of Cancer Immunotherapy.

Colin Pritchard. How Can Genomics Guide Decision-Making in the Application of Immunotherapy?

Scott N. Gettinger. Overcoming Primary and Acquired Immune Resistance in the Clinic.

Dung T. Le. Integrating Immunotherapy Into the Treatment of Patients with MSI High Solid Tumors.

Katy K. Tsai. How Will Today’s Presentations Impact Clinical Practice?

Matthew D. Hellmann. Biomarkers for Activity of Immunotherapy in Lung Cancer.

Johann S. De Bono. Principles of Clinical Trial Design in the Era of Immunotherapy and Molecular Targets for Cancer.

Sunandana Chandra. Immunotherapy to Treat Metastatic Melanoma to the Brain

Antoni Ribas. How Melanoma Resists Immune Attack and Implications for Treatment.

Lisa H. Butterfield. Selection and Testing of Optimal Correlates to Immunotherapy Trials: Optional or Critical, Integrated or Integral?

Mary L. (Nora) Disis. Immunology 101: The Basics.

 

 

© 2016. Ассоциация специалистов по проблемам
меланомы. Все права защищены.